We propose that SCR inhibits estrogen biosynthesis via modulating the PI3K-aromatase pathway, thereby mitigating breast cancer progression (Figures 9, 10; Supplementary Table S2). The gene discussed is CYP19A1; the disease is breast carcinoma.